Estrella Immunopharma, Inc.
ESLA
$0.96
-$0.0095-0.98%
NASDAQ
| 06/30/2025 | 03/31/2025 | 09/30/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | 30.74% | 30.74% | 355.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -12.71% | -12.71% | -34.23% |
| Operating Income | -- | -- | 12.71% | 12.71% | 34.23% |
| Income Before Tax | -- | -- | 12.71% | 12.71% | 34.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 12.69% | 12.69% | 34.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 12.69% | 12.69% | 34.21% |
| EBIT | -- | -- | 12.71% | 12.71% | 34.23% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -- | -- | 99.21% | 99.21% | 96.96% |
| Normalized Basic EPS | -- | -- | 99.21% | 99.21% | 96.96% |
| EPS Diluted | -- | -- | 99.21% | 99.21% | 96.96% |
| Normalized Diluted EPS | -- | -- | 99.21% | 99.21% | 96.96% |
| Average Basic Shares Outstanding | -- | -- | 6,557.94% | 6,564.85% | 9,036.59% |
| Average Diluted Shares Outstanding | -- | -- | 6,557.94% | 6,564.85% | 9,036.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |